The global biosimilar monoclonal antibodies market was valued at US$ 1,516.9 Mn in 2016 and is projected to reach US$ 32,015.0 Mn in 2026 at a CAGR of 35.7% from 2017 to 2026. The Adalimumab drug class segment is estimated to account for the major revenue share of 29.1% by end of 2017, owing to its cost-effectiveness and capability to cure oncological diseases, Crohn’s colitis disease, and spondylitis.
Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies. A monovalent antibody can be antibody with the affinity that can bind the same epitope, antigen, or strain of microorganism that is recognized by the antibody.
Factors driving the growth of the global biosimilars monoclonal antibodies market include low-cost alternatives that enable patients to reduce their cost burden as compared to that required to afford conventional patented drugs. Also, several generic biologics/monopoly drugs are reaching expiry date of the patents, and the patents of various drugs have already expired. This opens up opportunities for various players in the global biosimilar drugs industry. Moreover, rising demand from emerging markets for low-cost medicines are opening up avenues for biosimilar drugs.
In addition, rising prevalence of chronic diseases such as oncological diseases, various types of cancers, etc., and various market key players investing in R&D activities for biosimilars are expected to fuel the growth of the global biosimilar monoclonal antibodies market over the forecast period.
However, high cost associated with the manufacturing process of these products, and unfavorable government regulations in developed regions such as the Americas may hamper the growth of the global biosimilar monoclonal antibodies market to an extent. Moreover, it is a challenge for new entrants to position themselves in this highly competitive market.
Companies profiled in the report are Allergan plc, BIOCADBioXpress, Therapeutics SA, Biocon, Boehringer Ingelheim GmbH, Celltrion Inc., Coherus BioSciences Inc., Dr. Reddy’s Laboratories Ltd., Genor BioPharma Co. Ltd., Intas Pharmaceuticals Limited, Novartis AG, Pfizer Inc., Reliance Life Sciences
